Cyclodextrins in nasal drug delivery

被引:162
作者
Merkus, FWHM [1 ]
Verhoef, JC [1 ]
Marttin, E [1 ]
Romeijn, SG [1 ]
van der Kuy, PHM [1 ]
Hermens, WAJJ [1 ]
Schipper, NGM [1 ]
机构
[1] Leiden Univ, Leiden Amsterdam Ctr Drug Res, NL-2300 RA Leiden, Netherlands
关键词
nasal drug absorption; nasal mucociliary clearance; methylated beta-cyclodextrins; interspecies differences; cyclodextrin toxicity; insulin;
D O I
10.1016/S0169-409X(98)00054-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nasal drug delivery is an attractive approach for the systemic delivery of high potency drugs with a low oral bioavailability due to extensive gastrointestinal breakdown and high hepatic first-pass effect. For lipophilic drugs nasal delivery is possible if they can be dissolved in the dosage form. Peptide and protein drugs often have a low nasal bioavailability because of their large size and hydrophilicity, resulting in poor transport properties across the nasal mucosa. Cyclodextrins are used to improve the nasal absorption of these drugs by increasing their aqueous solubility and/or by enhancing their nasal absorption. With several cyclodextrins very efficient nasal drug absorption has been reported, but also large interspecies differences have been found. Studies concerning the safety of cyclodextrins in nasal drug formulations demonstrate the non-toxicity of the cyclodextrins and also clinical data show no adverse effects. Therefore, some cyclodextrins can be expected to become effective and safe excipients in nasal drug delivery. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:41 / 57
页数:17
相关论文
共 81 条
[1]   BIOAVAILABILITY OF LEUPROLIDE ACETATE FOLLOWING NASAL AND INHALATION DELIVERY TO RATS AND HEALTHY HUMANS [J].
ADJEI, A ;
SUNDBERG, D ;
MILLER, J ;
CHUN, A .
PHARMACEUTICAL RESEARCH, 1992, 9 (02) :244-249
[2]   Cyclodextrin derivatives in pharmaceutics [J].
Albers, E ;
Muller, BW .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 1995, 12 (04) :311-337
[3]  
[Anonymous], P 4 INT S CYCL 1988
[4]  
Antlsperger G., 1996, P 8 INT S CYCL, P149
[5]   INTRANASAL ADMINISTRATION OF INSULIN WITH PHOSPHOLIPID AS ABSORPTION ENHANCER - PHARMACOKINETICS IN NORMAL SUBJECTS [J].
DREJER, K ;
VAAG, A ;
BECH, K ;
HANSEN, P ;
SORENSEN, AR ;
MYGIND, N .
DIABETIC MEDICINE, 1992, 9 (04) :335-340
[6]   PHARMACEUTICAL USES OF CYCLODEXTRINS AND DERIVATIVES [J].
DUCHENE, D ;
WOUESSIDJEWE, D .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1990, 16 (17) :2487-2499
[7]  
DUCHENE D, 1990, PHARM TECHNOL IN JUN, P21
[8]   MUCOCILIARY CLEARANCE IN THE CANINE LUNG DURING AND AFTER GENERAL-ANESTHESIA [J].
FORBES, AR ;
GAMSU, G .
ANESTHESIOLOGY, 1979, 50 (01) :26-29
[9]  
FRANK DW, 1976, AM J PATHOL, V83, P367
[10]   THE EFFECT OF PARENTERALLY ADMINISTERED CYCLODEXTRINS ON CHOLESTEROL LEVELS IN THE RAT [J].
FRIJLINK, HW ;
EISSENS, AC ;
HEFTING, NR ;
POELSTRA, K ;
LERK, CF ;
MEIJER, DKF .
PHARMACEUTICAL RESEARCH, 1991, 8 (01) :9-16